Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,484 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched Placebo (Capsules) Clear all
Terminated Not applicable Interventional Results available

Topiramate for Alcohol Use in Posttraumatic Stress Disorder

NCT01408641
View directory record Official record
Conditions
Alcohol Dependence, Alcoholism, Alcohol Abuse, Alcohol Use Disorder, PTSD, Posttraumatic Stress Disorder
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03241342
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
GTx 024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT03219320
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
NYX-2925, Placebo
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
152
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments

NCT01490697
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Mifepristone, d-Cycloserine, Placebo-matching Mifepristone, Placebo-matching d-Cycloserine (DCS)
Drug
Lead sponsor
Roger K. Pitman, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 3, 2026, 4:51 AM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 3, 2026, 4:51 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects

NCT04043338
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XC130-A10H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 3, 2026, 4:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Melatonin Treatment for Night-Eating Syndrome

NCT02500017
View directory record Official record
Conditions
Night-eating Syndrome
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

NCT03301298
View directory record Official record
Conditions
Healthy
Interventions
SXC-2023, Placebo oral capsule
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin for Bipolar & Cannabis Use Disorders

NCT03334721
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
Interventions
Gabapentin, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 3, 2026, 4:51 AM EDT
Recruiting Phase 2 Interventional

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

NCT07041281
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension
Interventions
spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 formulated capsule, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Apathy in Dementia Methylphenidate Trial (ADMET)

NCT01117181
View directory record Official record
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, placebo, Psychosocial intervention
Drug · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

NCT02504931
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

NCT05077865
View directory record Official record
Conditions
Hashimoto Disease
Interventions
MYMD-1, Placebo
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 3, 2026, 4:51 AM EDT
Terminated Phase 1Phase 2 Interventional

Nicotinamide Riboside for Diabetic Neuropathy

NCT03685253
View directory record Official record
Conditions
Diabetic Neuropathy Peripheral
Interventions
Niagen, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

NCT06258265
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 3, 2026, 4:51 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 3, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

NCT01335477
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Barbara, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 3, 2026, 4:51 AM EDT